Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-10-01 Epub Date: 2024-09-26 DOI:10.1007/s11864-024-01261-w

Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager, Fortunato Ciardiello, Alfredo Falcone, Mark Saunders, Nadia Amellal, Lucas Roby, Josep Tabernero, Per Pfeiffer

{"title":"Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.","authors":"Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager, Fortunato Ciardiello, Alfredo Falcone, Mark Saunders, Nadia Amellal, Lucas Roby, Josep Tabernero, Per Pfeiffer","doi":"10.1007/s11864-024-01261-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line, the SUNLIGHT trial showed that trifluridine/tipiracil + bevacizumab (FTD/TPI + BEV) provided significant survival benefits and as such is now a recommended third line regimen in patients with refractory mCRC, irrespective of RAS mutational status and previous anti-VEGF treatment. Some patients are not candidates for intensive combination chemotherapy as first-line therapy due to age, low tumor burden, performance status and/or comorbidities. Capecitabine (CAP) + BEV is recommended in these patients. In the SOLSTICE trial, FTD/TPI + BEV as a first line regimen in patients not eligible for intensive therapy was not superior to CAP + BEV in terms of progression-free survival (PFS). However, in SOLSTICE, FTD/TPI + BEV resulted in similar PFS, overall survival, and maintenance of quality of life as CAP + BEV, with a different safety profile. FTD/TPI + BEV offers a possible first line alternative in patients for whom CAP + BEV is an unsuitable treatment. This narrative review explores and summarizes the clinical trial data on FTD/TPI + BEV.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"1312-1322"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485186/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01261-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line, the SUNLIGHT trial showed that trifluridine/tipiracil + bevacizumab (FTD/TPI + BEV) provided significant survival benefits and as such is now a recommended third line regimen in patients with refractory mCRC, irrespective of RAS mutational status and previous anti-VEGF treatment. Some patients are not candidates for intensive combination chemotherapy as first-line therapy due to age, low tumor burden, performance status and/or comorbidities. Capecitabine (CAP) + BEV is recommended in these patients. In the SOLSTICE trial, FTD/TPI + BEV as a first line regimen in patients not eligible for intensive therapy was not superior to CAP + BEV in terms of progression-free survival (PFS). However, in SOLSTICE, FTD/TPI + BEV resulted in similar PFS, overall survival, and maintenance of quality of life as CAP + BEV, with a different safety profile. FTD/TPI + BEV offers a possible first line alternative in patients for whom CAP + BEV is an unsuitable treatment. This narrative review explores and summarizes the clinical trial data on FTD/TPI + BEV.

查看原文本刊更多论文

FTD/TPI + 贝伐珠单抗联合疗法在不可切除转移性结直肠癌治疗中的临床试验数据回顾。

意见陈述：推荐的不可切除转移性结直肠癌（mCRC）一线和二线治疗方法包括以氟尿嘧啶为基础的化疗、以抗血管内皮生长因子（VEGF）为基础的治疗和抗表皮生长因子受体靶向治疗。在三线治疗中，SUNLIGHT 试验表明，三氟啶/替比西嘧啶+贝伐单抗（FTD/TPI+BEV）可显著提高患者的生存率，因此目前已成为难治性 mCRC 患者的推荐三线治疗方案，无论患者的 RAS 突变状态如何，既往是否接受过抗血管内皮生长因子治疗。有些患者由于年龄、肿瘤负荷低、表现状态和/或合并症等原因，不适合将强化联合化疗作为一线疗法。对于这些患者，推荐使用卡培他滨（CAP）+ BEV。在 SOLSTICE 试验中，对于不符合强化治疗条件的患者，FTD/TPI + BEV 作为一线治疗方案在无进展生存期（PFS）方面并不优于 CAP + BEV。然而，在 SOLSTICE 试验中，FTD/TPI + BEV 的无进展生存期、总生存期和生活质量维持率与 CAP + BEV 相似，但安全性有所不同。FTD/TPI+BEV为不适合接受CAP+BEV治疗的患者提供了一种可能的一线替代方案。本综述探讨并总结了 FTD/TPI + BEV 的临床试验数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.